netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 4: Central nervous system - Full Chapter
Chapter Links...
 Details...
04.03.04  Expand sub section  Other antidepressant drugs
Duloxetine (Cymbalta)
(Depression, anxiety)
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Non-formulary
  • RNOH:
    • Restricted
  • UCLH:
  • WH:
    • Non-formulary
 
   
Flupentixol tab
(Antidepressant)
View adult BNF View SPC online View childrens BNF
Formulary

NOTE: There is more than one monograph for this medicine, click here to search for formulary status and its use for other indications. 

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • Initiate after discussion with liaison psychiatry team.
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
  • CIFT approvals:
    • Depression
  • BEHMT approvals:
    • Depression
 
   
Mirtazapine
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

Provider notes

  • NMUH:
    • See link below
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
  • CIFT approvals:
    • Major depression
  • BEHMT approvals:
    • Major depression
 
Link  NMUH: Depression Guidelines
   
Reboxetine
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • No restriction stated
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
  • CIFT approvals:
    • Major depression
  • BEHMT approvals:
    • Major depression
 
   
Venlafaxine immediate release
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • No restriction stated
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • Restricted for initiation by a Consultant Psychiatrist only
  • CIFT approvals:
    • 1st/2nd line for Generalised Anxiety Disorder (GAD) (off-label)
    • 1st/2nd line for panic disorder (off-label)
    • 1st/2nd line for social anxiety disorder
  • BEHMT approvals:
    •  Not specified but used for licensed indication 
 
   
Venlafaxine modified release
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • Non-formulary
  • RNOH:
    • No restriction stated
  • UCLH:
  • WH:
    • As per Islington and Haringey CCGs Medicines Management plan
  • CIFT approvals:
    • 1st/2nd line for Generalised Anxiety Disorder (GAD) (off-label)
    • 1st/2nd line for panic disorder (off-label)
    • 1st/2nd line for social anxiety disorder
  • BEHMT approvals:
    •  Not specified but used for licensed indication
 
   
 ....
 Non Formulary Items
Agomelatine

View adult BNF View SPC online View childrens BNF
Non Formulary
Link  NICE TA231 (not recommended): Agomelatine for the treatment of major depressive episodes (terminated appraisal)
 
Tryptophan

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary